Abstract
Aim
To determine whether there is an association between complement factor H (CFH) or LOC387715 genotypes and response to treatment with photodynamic therapy (PDT) for exudative age-related macular degeneration (AMD).
Methods
Sixty-nine patients being treated for neovascular AMD with PDT were genotyped for the CFH Y402H and LOC387715 A69S polymorphisms by allele-specific digestion of PCR products. AMD phenotypes were characterized by clinical examination, fundus photography, and fluorescein angiography.
Results
Adjusting for age, pre-PDT visual acuity (VA), and lesion type, mean VA after PDT was significantly worse for the CFH TT genotype than for the TC or CC genotypes (P=0.05). Post-PDT VA was significantly worse for the CFH TT genotype in the subgroup of patients with predominantly classic choroidal neovascular lesions (P=0.04), but not for the patients with occult lesions (P=0.22). For the LOC387715 A69S variant, there was no significant difference among the genotypes in response to PDT therapy.
Conclusions
The CFH Y402H variant was associated with a response to PDT treatment in this study. Patients with the CFH TT genotype fared significantly worse with PDT than did those with the CFH TC and CC genotypes, suggesting a potential relationship between CFH genotype and response to PDT.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Bressler NM, Bressler SB, Fine SL . Age-related macular degeneration. Surv Ophthalmol 1988; 32: 375–413.
Klein RJ, Zeiss C, Chew EY, Tsai J-Y, Sackler RS, Haynes C et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308: 385–389.
Edwards AO, Ritter III R, Abel KJ, Manning A, Panhuysen C, Farrer LA . Complement factor H polymorphism and age-related macular degeneration. Science 2005; 308: 421–424.
Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005; 308: 419–421.
Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 2005; 102: 7227–7232.
Souied EH, Levziel N, Richard F, Dragon-Durey M-A, Coscas G, Soubrane G et al. Y402H complement factor H polymorphism associated with exudative age-related macular degeneration in the French population. Mol Vis 2005; 11: 1135–1140.
Lau L-I, Chen S-J, Cheng C-Y, Yen M-Y, Lee F-L, Lin M-W et al. Association of the Y402H polymorphism in complement factor H gene and neovascular age-related macular degeneration in Chinese patients. Invest Ophthalmol Vis Sci 2006; 47: 3242–3246.
Postel EA, Agarwal A, Caldwell J, Gallins P, Toth C, Schmidt S et al. Complement factor H increases risk for atrophic age-related macular degeneration. Ophthalmology 2006; 113: 1504–1507.
Seddon JM, Francis PJ, George S, Schultz DW, Rosner B, Klein ML . Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration. JAMA 2007; 297: 1793–1800.
Wegscheider BJ, Weger M, Renner W, Steinbrugger I, März W, Mossböck G et al. Association of complement factor H Y402H gene polymorphism with different subtypes of exudative age-related macular degeneration. Ophthalmology 2007; 114: 738–742.
Goverdhan SV, Hannan S, Newsom RB, Luff AJ, Griffiths H, Lotery AJ . An analysis of the CFH Y402H genotype in AMD patients and controls from the UK, and response to PDT treatment. Eye 2007, e-pub ahead of print April 2007.
Brantley Jr MA, Edelstein SL, King JM, Apte RS, Kymes SM, Shiels A . Clinical phenotypes associated with the complement factor H Y402H variant in age-related macular degeneration. Am J Ophthalmol 2007; 144: 404–408.
Brantley Jr MA, Fang AM, King JM, Tewari A, Kymes SM, Shiels A . Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 2007; 114: 2168–2173.
Jakobsdittr J, Conley YP, Weeks DE, Mah TS, Ferrell RE, Gorin MB . Susceptibility genes for age-related macular degeneration on chromosome 10q26. Am J Hum Genet 2005; 77: 389–407.
Rivera A, Fisher SA, Fritsche LG, Keilhauer CN, Lichtner P, Meitinger T et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet 2005; 14: 3227–3236.
DeWan A, Liu M, Hartman S, Zhang SS-M, Liu DTL, Zhao C et al. HTRA1 promoter polymorphism in wet age-related macular degeneration. Science 2006; 314: 989–992.
Yang Z, Camp NJ, Sun H, Tong Z, Gibbs D, Cameron DJ et al. A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science 2006; 314: 892–893.
Virgili G, Do DV, Bressler NM, Menchini U . New therapies for neovascular age-related macular degeneration: critical appraisal of the current evidence. Acta Ophthalmol Scand 2007; 85: 6–20.
Verteporfin Roundtable Participants. Guidelines for using verteporfind (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina 2005; 25: 119–134.
Bressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish GE, Gragoudas ES et al. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes—TAP report no. 3. Arch Ophthalmol 2002; 120: 1443–1454.
Acknowledgements
This study was supported by NEI Grant EY012284, NEI Core Grant 5 P30 EY02687, and a grant from Research to Prevent Blindness to the Department of Ophthalmology and Visual Sciences at Washington University School of Medicine. No conflicting relationship exists for any author.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brantley, M., Edelstein, S., King, J. et al. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy. Eye 23, 626–631 (2009). https://doi.org/10.1038/eye.2008.28
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/eye.2008.28
Keywords
This article is cited by
-
Association of an age-related maculopathy susceptibility 2 gene variant with the 12-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy
Japanese Journal of Ophthalmology (2019)
-
A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration
Scientific Reports (2017)
-
The role of glial cells and the complement system in retinal diseases and Alzheimer’s disease: common neural degeneration mechanisms
Experimental Brain Research (2014)
-
The significance of the complement system for the pathogenesis of age-related macular degeneration — current evidence and translation into clinical application
Graefe's Archive for Clinical and Experimental Ophthalmology (2011)
-
Genetic Predictors of Response to Photodynamic Therapy
Molecular Diagnosis & Therapy (2011)
